Moorlands volunteers wanted to take part in Covid vaccine study

By Jack Lenton

13th May 2021 | Local News

Volunteers from across Staffordshire are being asked to sign up to the latest Covid-19 vaccine study to be rolled out across the UK.

The National Institute for Health Research (NIHR) supported Valneva Phase 3 study is open to volunteers who are aged 18 and over and in stable health.

Midlands Partnership NHS Foundation Trust (MPFT) will run the study at Cheadle Hospital and hope to recruit 120 local volunteers.

Everyone who participates in this study will receive a vaccine. Participants aged 30 and older will receive either the Covid-19 vaccination developed by Valneva (VLA2001) or a nationally approved Covid-19 vaccine developed by AstraZeneca (AZD1222). These participants will not know which vaccine they have received. All participants under 30 will receive the VLA2001 vaccine.

Professor Toby Helliwell, Principal Investigator for the study at MPFT said "Myself and the study team here at MPFT are delighted to be leading the Valneva study in Staffordshire and to play our part in testing a further vaccine candidate to help protect the population against Covid-19. It is vital that research studies continue to ensure that we have effective vaccines that work for everybody.

"Every participant involved in the study is key to helping us gain a detailed understanding of how the vaccine will perform in a large population. People from all backgrounds are needed to take part in this and future vaccine studies.

"If you are interested in taking part in vaccine studies, please sign up to the NHS Vaccine Research Registry. It's very quick and simple to do."

Ruth Lambley-Burke, Head of Research and Innovation at the Trust added: "Clinical research is extremely important in the fight against COVID-19 and we are pleased to play our role in the Valneva clinical study in the West Midlands."

Professor Adam Finn, Chief Investigator for the Valneva study said, "Following very encouraging safety and immune response results from our phase 1 study, along with my investigator colleagues, I am really looking forward to starting on this important next stage of the clinical development of this important new vaccine. We definitely need more vaccines to help us out of this pandemic and this one is a very promising candidate."

Professor Matthew Brookes, Clinical Director of the NIHR Clinical Research Network West Midlands added, "Clinical studies into COVID-19 vaccines remain critical to help find several safe and effective candidates to help protect us all. Volunteers in the West Midlands are still needed to help carry out these studies and we are very grateful to the more than 30,000 who have already signed up."

For more information about the study or to register your interest, please contact the MPFT Research team on:

Phone: 0808 196 3890

Email: [email protected]

Don't forget to sign up to our newsletter below!  

You can submit your own news and opinions straight to Leek Nub News by using the 'Nub It' button on our home page.

This can also be done for events on our What's On page and for businesses, groups and organisations on our Local Listings page, also by using the 'Nub It' button.

Please like and follow our online newspaper on your favourite social media channel. You can find us on Facebook and Twitter.

     

New leek Jobs Section Launched!!
Vacancies updated hourly!!
Click here: leek jobs

Share:

Related Articles

Tigerbite, in Leek, has extended its opening hours to meet customer needs (Tigerbite).
Local News

Popular Leek takeaway extends opening hours to meet community needs

Hen Cloud House Care Home will host an open day on 17 August (Borough Care).
Local News

Beautiful Leek care home to host open day this month

Sign-Up for our FREE Newsletter

We want to provide leek with more and more clickbait-free local news.
To do that, we need a loyal newsletter following.
Help us survive and sign up to our FREE weekly newsletter.

Already subscribed? Thank you. Just press X or click here.
We won't pass your details on to anyone else.
By clicking the Subscribe button you agree to our Privacy Policy.